



Supplemental Fig. S4. Subgroup analysis of end-stage kidney disease in the studies longer than 52 weeks. (A) Absolute risks and (B) rank probabilities of the treatments. DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor.